AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940

Phase 2

Completed

Conditions: Pain

Interventions: Drug: AZD1940
Drug: Placebo
Drug: Naproxen

First Posted Date: 2008-04-16

Last Posted Date: 2012-06-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 151

Registration Number: NCT00659490

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2008-04-16

Last Posted Date: 2016-12-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 106

Registration Number: NCT00659048

Locations: 🇺🇸
Altana/Nycomed, San Antonio, Texas, United States

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

Phase 3

Completed

Conditions: Hay Fever
Rhinitis, Allergic, Seasonal

Interventions: Drug: Ciclesonide
Drug: Placebo

First Posted Date: 2008-04-16

Last Posted Date: 2016-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 500

Registration Number: NCT00659594

Locations: 🇨🇦
Altana/Nycomed, Mississauga, Ontario, Canada

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial
Hay Fever

Interventions: Drug: Ciclesonide nasal
Drug: Placebo

First Posted Date: 2008-04-16

Last Posted Date: 2016-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 120

Registration Number: NCT00658918

Locations: 🇺🇸
Altana/Nycomed, Little Rock, Arkansas, United States

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2008-04-16

Last Posted Date: 2016-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 418

Registration Number: NCT00659750

Locations: 🇺🇸
Altana/Nycomed, Madison, Wisconsin, United States

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal
Hay Fever

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2008-04-16

Last Posted Date: 2016-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 302

Registration Number: NCT00659841

Locations: 🇺🇸
Altana/Nycomed, San Antonio, Texas, United States

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Exenatide

First Posted Date: 2008-04-14

Last Posted Date: 2020-12-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 122

Registration Number: NCT00658021

Locations: 🇿🇦
Research Site, Verulam, South Africa

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Phase 3

Completed

Conditions: Non-metastatic Prostate Cancer

Interventions: Drug: Placebo
Drug: Bicalutamide

First Posted Date: 2008-04-14

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 3618

Registration Number: NCT00657904

Locations: 🇨🇦
Research Site, Quebec, Canada

Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease

Phase 3

Completed

Conditions: Myocardial Ischaemia
Coronary Artery Disease

Interventions: Drug: Rosuvastatin
Behavioral: Cholesterol lowering diet

First Posted Date: 2008-04-14

Last Posted Date: 2009-03-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 280

Registration Number: NCT00657527

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

Phase 2

Completed

Conditions: Stable Asthma

Interventions: Drug: formoterol
Drug: budesonide/formoterol

First Posted Date: 2008-04-14

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 175

Registration Number: NCT00658255

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy